ZIVO vs. IMMP, PRME, SLRN, ANNX, ITOS, CDTX, ACB, TSVT, CRDF, and OLMA
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Immutep (IMMP), Prime Medicine (PRME), Acelyrin (SLRN), Annexon (ANNX), iTeos Therapeutics (ITOS), Cidara Therapeutics (CDTX), Aurora Cannabis (ACB), 2seventy bio (TSVT), Cardiff Oncology (CRDF), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs.
ZIVO Bioscience (NASDAQ:ZIVO) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.
Immutep has a consensus target price of $8.50, indicating a potential upside of 356.99%. Given Immutep's stronger consensus rating and higher possible upside, analysts clearly believe Immutep is more favorable than ZIVO Bioscience.
ZIVO Bioscience has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500.
ZIVO Bioscience has higher earnings, but lower revenue than Immutep.
Immutep received 213 more outperform votes than ZIVO Bioscience when rated by MarketBeat users. Likewise, 72.56% of users gave Immutep an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.
12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 2.3% of Immutep shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by insiders. Comparatively, 3.1% of Immutep shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Immutep had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Immutep and 0 mentions for ZIVO Bioscience. Immutep's average media sentiment score of 0.87 beat ZIVO Bioscience's score of 0.00 indicating that Immutep is being referred to more favorably in the news media.
Summary
Immutep beats ZIVO Bioscience on 10 of the 14 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 3/29/2025 by MarketBeat.com Staff
